Wspólnotowy Serwis Informacyjny Badan i Rozwoju - CORDIS

  • Komisja Europejska
  • CORDIS
  • Projekty i wyniki
  • Final Report Summary - AUTOROME (From Immune Responses in Rare Autoimmune Diseases to novel Therapeutic Intervention Strategies-a personalized Medicine approach)
FP6

AUTOROME Streszczenie raportu

Project ID: 5264
Źródło dofinansowania: FP6-LIFESCIHEALTH
Kraj: Germany

Final Report Summary - AUTOROME (From Immune Responses in Rare Autoimmune Diseases to novel Therapeutic Intervention Strategies-a personalized Medicine approach)

AUTOROME was a multipartner research and demonstration project utilising the post-genomic tools to identify pathophysiological mechanisms of rare autoimmune diseases and eventually, develop perspectives for new diagnostic and therapeutic approaches. The diseases the consortium concentrated on studying were rare autoimmune diseases such as Systemic lupus erythematosus (SLE), Systemic scleroderma (SSC), Anti-phospholipid syndrome (APS), Autoimmune lymphoproliferative syndrome (ALPS) and Stiff-Person syndrome (SPS) all being antibody mediated autoimmune diseases. The concerted actions taken by the consortium led to a more comprehensive understanding of molecular processes that determine an autoimmune disease. In particular, a strategic concept and workflow has evolved by studying rare autoimmune diseases in depth leading to improved sub-typing of autoimmune diseases using T cell receptor typing and high density peptide profiling for testing autoantibody repertoires. Data sets have been filed with excess to clinical parameters to analyse the interplay of genetic and environmental factors occurring in the pathogenesis of autoimmune diseases.

To our knowledge, the initiative has been outstanding in its conceptual design. State-of-the-art technologies of which several are proprietary to Small and medium-sized enterprises (SMEs) were brought together to generate within a concerted action comprehensive data sets for describing rare autoimmune diseases on the humoral, cellular and molecular level. The initiative has been driven by the notion that genomic information that is unique to each human being might contribute in interplay with life style factors to the pathogenesis of rare autoimmune diseases.

The initiative integrated knowledge established over the last 20 years, reanalyses this knowledge with cutting-edge technologies that have been established within the last years, such as genome-wide expression profilings, high density epitope mapping, immunoscope analysis, genome-wide SNP screens as well as mass spectrometric driven structure-function analysis. All information has been collected in the data base (please see http://www.autorome.de online) accessible to the members of the consortium.

The work in the AUTOROME consortium has allowed its participants to work in an European setting of high quality research. Because of the European research funding and the exchange with our collaborators, the AUTOROME consortium was able to establish the following achievements such as e.g. reduction of sCD21 as a marker of autoimmunity and determined biochemical characteristics and mechanisms of shedding of CD21.

Powiązane informacje

Kontakt

Hans-juergen THIESEN, (Director)
Tel.: +49-3814945870
Faks: +49-3814945882
Adres e-mail
Śledź nas na: RSS Facebook Twitter YouTube Zarządzany przez Urząd Publikacji UE W górę